Inhibiting the activity of SLC13A3, or pharmacologically interfering with its function, can increase the sensitivity of tumor cells to ferroptosis, curb tumor progression, and enhance the effectiveness of ICB (104). Here, SLC13A3 is linked to neoplasm.